Published in Infect Immun on December 11, 2006
Evidence of purifying selection on merozoite surface protein 8 (MSP8) and 10 (MSP10) in Plasmodium spp. Infect Genet Evol (2012) 1.01
Genetic diversity of Plasmodium vivax and Plasmodium falciparum in Honduras. Malar J (2012) 0.94
Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response. Infect Immun (2009) 0.89
Antibody responses to the merozoite surface protein-1 complex in cerebral malaria patients in India. Malar J (2008) 0.87
Vaccines against a Major Cause of Abortion in Cattle, Neospora caninum Infection. Animals (Basel) (2011) 0.86
Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate. Vaccine (2010) 0.83
Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24. Clin Vaccine Immunol (2014) 0.83
Designing malaria vaccines to circumvent antigen variability. Vaccine (2015) 0.83
A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies. Infect Immun (2013) 0.82
Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus. Malar J (2011) 0.82
Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection. Vaccine (2010) 0.81
Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8. Infect Immun (2012) 0.81
A hybrid multistage protein vaccine induces protective immunity against murine malaria. Infect Immun (2012) 0.81
Antibody responses to 43 and 48 kDa antigens of blood-stage Plasmodium berghei in Balb/c mice. J Parasit Dis (2010) 0.78
Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Malar J (2016) 0.75
The pathogenic basis of malaria. Nature (2002) 10.44
A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med (1990) 4.90
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun (2002) 4.02
Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun (1996) 3.64
Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg (1994) 3.13
Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun (2002) 3.08
Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med (2001) 2.80
A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun (1996) 2.60
Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect Immun (2004) 2.59
A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infect Immun (1993) 2.57
Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex. Mol Biochem Parasitol (1987) 2.56
Progress and challenges for malaria vaccines. Nature (2002) 2.50
Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med (1995) 2.48
Passive immunization against murine malaria with an IgG3 monoclonal antibody. J Immunol (1984) 2.40
The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor. J Exp Med (1984) 2.40
Parasite ligand-host receptor interactions during invasion of erythrocytes by Plasmodium merozoites. Int J Parasitol (2004) 2.37
Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol Microbiol (2004) 2.24
Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol (1995) 2.23
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine (2005) 2.18
Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species. Nat Med (2000) 2.15
Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1. Mol Biochem Parasitol (1993) 2.14
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun (2006) 2.02
Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun (2001) 1.81
Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol (1995) 1.79
Epitope map and processing scheme for the 195,000-dalton surface glycoprotein of Plasmodium falciparum merozoites deduced from cloned overlapping segments of the gene. Proc Natl Acad Sci U S A (1986) 1.77
Conformational changes associated with proteolytic processing of presecretory proteins allow glutathione-catalyzed formation of native disulfide bonds. J Biol Chem (1982) 1.72
Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect Immun (2000) 1.71
Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infect Immun (1997) 1.71
Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine (2005) 1.68
Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine. Mol Biochem Parasitol (2003) 1.60
Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine (2006) 1.33
The increased susceptibility of young red cells to invasion by the malarial parasite Plasmodium falciparum. Br J Haematol (1980) 1.32
Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Infect Immun (1996) 1.29
Cloning and analysis of the gene encoding the 230-kilodalton merozoite surface antigen of Plasmodium yoelii. Mol Biochem Parasitol (1989) 1.27
Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Infect Immun (1996) 1.17
Variant genes and the spleen in Plasmodium vivax malaria. Int J Parasitol (2004) 1.16
Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J Exp Biol (2003) 1.14
Merozoite surface protein 8 of Plasmodium falciparum contains two epidermal growth factor-like domains. Mol Biochem Parasitol (2001) 1.11
Plasmodium falciparum merozoite surface protein 8 is a ring-stage membrane protein that localizes to the parasitophorous vacuole of infected erythrocytes. Infect Immun (2005) 1.10
Protective antigens of rodent and human bloodstage malaria. Philos Trans R Soc Lond B Biol Sci (1984) 1.07
A common cross-species function for the double epidermal growth factor-like modules of the highly divergent plasmodium surface proteins MSP-1 and MSP-8. J Biol Chem (2004) 1.04
Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4. Infect Immun (2004) 1.00
Protective immunity against Plasmodium yoelii malaria induced by immunization with particulate blood-stage antigens. Infect Immun (1997) 1.00
A protective glycosylphosphatidylinositol-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains. Infect Immun (2000) 0.98
Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1. Vaccine (2003) 0.98
Plasmodium vivax merozoite surface protein 8 cloning, expression, and characterisation. Biochem Biophys Res Commun (2004) 0.94
Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites. Infect Immun (2005) 0.89
MSP8 is a non-essential merozoite surface protein in Plasmodium falciparum. Mol Biochem Parasitol (2005) 0.87
Merozoite antigens involved in invasion. Chem Immunol (2002) 0.84
Expression, localization, and erythrocyte binding activity of Plasmodium yoelii merozoite surface protein-8. Mol Biochem Parasitol (2006) 0.83
P. falciparum: merozoite surface protein-8 peptides bind specifically to human erythrocytes. Peptides (2003) 0.78
Sustaining and broadening intervention impact: a longitudinal randomized trial of 3 adolescent risk reduction approaches. Pediatrics (2003) 2.29
Longitudinal influence of perceptions of peer and parental factors on African American adolescent risk involvement. J Urban Health (2002) 2.05
Host-parasite interactions revealed by Plasmodium falciparum metabolomics. Cell Host Microbe (2009) 2.00
PERK-dependent regulation of lipogenesis during mouse mammary gland development and adipocyte differentiation. Proc Natl Acad Sci U S A (2008) 1.66
Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection. J Immunol (2008) 0.98
Gammadelta T cells but not NK cells are essential for cell-mediated immunity against Plasmodium chabaudi malaria. Infect Immun (2010) 0.93
Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites. Infect Immun (2005) 0.89
Plasmodium chabaudi adami: interferon-gamma but not IL-2 is essential for the expression of cell-mediated immunity against blood-stage parasites in mice. Exp Parasitol (2003) 0.88
Analysis of antigen-specific antibodies and their isotypes in experimental malaria. Cytometry A (2007) 0.87
Immunity to blood-stage murine malarial parasites is MHC class II dependent. Immunol Lett (2003) 0.86
Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses. Clin Vaccine Immunol (2008) 0.85
Members of the merozoite surface protein 7 family with similar expression patterns differ in ability to protect against Plasmodium yoelii malaria. Infect Immun (2004) 0.84
Molecular cloning of a Trypanosoma cruzi cell surface casein kinase II substrate, Tc-1, involved in cellular infection. Infect Immun (2006) 0.84
Elevated levels of the Plasmodium yoelii homologue of macrophage migration inhibitory factor attenuate blood-stage malaria. Infect Immun (2010) 0.83
Expression, localization, and erythrocyte binding activity of Plasmodium yoelii merozoite surface protein-8. Mol Biochem Parasitol (2006) 0.83
A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies. Infect Immun (2013) 0.82
Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8. Infect Immun (2012) 0.81
Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection. Vaccine (2010) 0.81
Survival of human pathogenic bacteria in different types of natural mineral water. J Water Health (2012) 0.81
Synthesis and solid state characterization of molecular rotors with steroidal stators: ethisterone and norethisterone. Org Biomol Chem (2010) 0.79
Anisochronous dynamics in a crystalline array of steroidal molecular rotors: evidence of correlated motion within 1D helical domains. J Am Chem Soc (2011) 0.78
CD28 costimulation is required for the expression of T-cell-dependent cell-mediated immunity against blood-stage Plasmodium chabaudi malaria parasites. Infect Immun (2004) 0.77
Remarkable stability in patterns of blood-stage gene expression during episodes of non-lethal Plasmodium yoelii malaria. Malar J (2012) 0.76
Synthesis and evaluation of molecular rotors with large and bulky tert-butyldiphenylsilyloxy-substituted trityl stators. J Org Chem (2012) 0.75